Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Cognition
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate of construct validity for a sample of patients with PD in Bogotá and Cali – Colombia.
Background: Parkinson´s disease (PD) is a neurodegenerative disorder characterized for heterogeneous cognitive impairment. Mild cognitive impairment (MCI) suggest a continuum from normal cognition to dementia therefore MCI could be considered prodromal state. Executive dysfunction is the most frequent type of cognitive deficit in PD as well as multidomain impairment. Moca Test is recommended to screening of cognitive impairment of patients with PD but this test is not studied in Colombia in such a way that is necessary to investigate if Moca Test is to be interpreted as a measure of cognitive impairment in our population.
Methods: Cross-sectional study. A factorial analysis was conducted on data of 110 patients. The KMO index was calculated and results was tested for factorial analysis. We tested a varimax rotation with a first matrix and promax rotation was done. We calculed Cronbach alpha for internal consistency.
Results: The mean of age 66.3 (SD 10,6) and frequency of sex was 65.3% men. All patients were evaluated for global cognition with Moca Test as a part of Neurological examination between July and December 2015. We calculated KMO index = 0,82. Variance was 56.1 explained for three major factors. With varimax rotation we found correlation between factors but promax rotation was done and final interpretation was better. The Cronbach alpha was = 0.51.
Conclusions: We found that Moca test have a not good internal consistency for assessment cognitive impairment in our population. However, results would be interpreted in two ways: first, population evaluated was heterogeneuous and years of education is a variable to modify the performance in the test. Secondly, we agree with MDS-Task Force criteria for MCI in PD and Moca Test would be used to screening and not to be a tool to diagnosed level of impairment in PD patients. More studies of Moca test are needed in our context.
To cite this abstract in AMA style:
B.E. Muñoz, O. Bernal, A. Castillo, J.L. Orozco. Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/construct-validity-of-moca-test-in-a-sample-of-patients-with-parkinsons-disease-in-bogot-and-cali-colombia/. Accessed July 18, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/construct-validity-of-moca-test-in-a-sample-of-patients-with-parkinsons-disease-in-bogot-and-cali-colombia/